Martin W. Schoen, MD, MPH

Articles by Martin W. Schoen, MD, MPH

Martin Schoen, MD, and Andrew W. Hahn, MD

Treatment Intensification in Vulnerable Populations: ARPI Use in Elderly, Frail, and High-Comorbidity Patients With mCSPC: With Martin Schoen, MD, and Andrew W. Hahn, MD

ByMartin W. Schoen, MD, MPH,Andrew W. Hahn, MD

June 30th 2026

Martin Schoen, MD, and Andrew W. Hahn, MD, discuss ARPI use in elderly, frail, and high-comorbidity patients with mCSPC

Martin W. Schoen, MD, MPH

Dr Schoen on a Real-World Study of Enzalutamide vs Apalutamide in mCSPC

ByMartin W. Schoen, MD, MPH

May 18th 2026

Martin W. Schoen, MD, MPH, discusses data from a real-world study of enzalutamide vs apalutamide in mCSPC.

Latest Updated Articles

Treatment Intensification in Vulnerable Populations: ARPI Use in Elderly, Frail, and High-Comorbidity Patients With mCSPC: With Martin Schoen, MD, and Andrew W. Hahn, MD
June 30th 2026

Trending on OncLive

FDA Grants Fast Track Designation to Pan-RAS Molecular Glue ERAS-0015 for Metastatic Pancreatic Adenocarcinoma

FDA Approves Zanidatamab-Based Regimens for First-Line HER2+ Locally Advanced or Metastatic Gastric Cancer

FDA Grants Priority Review to Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer

European Commission Approves Sacituzumab Govitecan Plus Pembrolizumab for Frontline PD-L1+ mTNBC

MOMENTUM Trial Aims to Add Further Evidence for Cemsidomide in R/R Myeloma